Ranbaxy Launches Acne Treatment Capsules in US
New Delhi: Drug firm Ranbaxy Laboratories on Wednesday launched a capsule used for treatment of severe acne in the US.
Ranbaxy Laboratories Inc, a subsidiary of the company, has announced the launch of Absorica capsules in the strengths of 25 mg and 35 mg in the US market.
"The product is licensed to Ranbaxy from Cipher Pharmaceuticals Inc," Ranbaxy Laboratories said in a statement.
"Since isotretinoin dosing is weight-based, we are most pleased to make available these valuable, additional dosing options exclusively for Absorica," Ranbaxy North America brand division vice president Ashish Anvekar said.
This will give prescribers enhanced flexibility to tailor the isotretinoin therapy depending on the patient's weight, and benefit the group of patients who are in that weight range, irrespective of their dietary intake, he added.
"The capsules are indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older," the company said.
The medicine must not be used by female patients who are or may become pregnant. Absorica is only available through a restricted distribution program called iPLEDGE, it added.
In April, Sun Pharmaceutical Industries had announced to acquire Ranbaxy Laboratories in a $4-billion deal.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
